Login / Signup

Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial.

Fredrik MöllerMarianne MånssonJonas WallströmMikael HellströmJonas HugossonRebecka Arnsrud Godtman
Published in: European urology (2024)
A non-negligible number of men with PSA 1.8-3ng/ml have clinically significant PC. Whether a delay in the diagnosis of these tumors until they reached PSA ≥3ng/ml would impair their chance of cure remains to be evaluated.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • study protocol
  • clinical trial
  • phase iii
  • phase ii
  • middle aged
  • randomized controlled trial
  • young adults
  • open label